rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

Bio Blast Pharma (ORPN)

70 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  2. [verwijderd] 15 april 2016 19:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Er wordt door de shorters krampachtig geprobeerd het aandeel naar beneden te duwen Toch gaan ze dit gevecht vandaag verliezen (PM loopt hiervoor al lang genoeg mee) en zullen ze vandaag en begin volgende week verder uitgerookt gaan worden verwacht PM.
  6. [verwijderd] 15 april 2016 20:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bio Blast Pharma Ltd (NASDAQ:ORPN) Given Average Rating of “Strong Buy” by Brokerages April 15th, 2016 - By Jesse Cantor - 0 comments Bio Blast Pharma logoBio Blast Pharma Ltd

    (NASDAQ:ORPN) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation. Brokerages have set a 1-year consensus price target of $23.00 for the company and are anticipating that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given Bio Blast Pharma an industry rank of 81 out of 265 based on the ratings given to related companies. Shares of Bio Blast Pharma (NASDAQ:ORPN) traded up 17.7167% during midday trading on Friday, reaching $2.8252. 4,456,673 shares of the company’s stock were exchanged. Bio Blast Pharma has a one year low of $2.16 and a one year high of $8.50. The stock’s 50-day moving average is $2.62 and its 200 day moving average is $3.77. The firm’s market cap is $40.20 million. Bio Blast Pharma (NASDAQ:ORPN) last posted its quarterly earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.09. Analysts anticipate that Bio Blast Pharma will post ($1.23) EPS for the current year. ORPN has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Bio Blast Pharma from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Sunday, January 17th. Rodman & Renshaw initiated coverage on shares of Bio Blast Pharma in a report on Thursday, January 28th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, HC Wainwright initiated coverage on shares of Bio Blast Pharma in a report on Thursday, January 28th. They issued a “buy” rating and a $25.00 target price on the stock.Bio Blast Pharma Ltd. (NASDAQ:ORPN) is a development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases - See more at: www.eurobench.com/Forum/Topic/1308695...
  9. wieweet 15 april 2016 20:52

    • wieweet

      Lid sinds: 16 jun 2005

      Laatste bezoek: 01 okt 2024

    • Aanbevelingen

      Ontvangen: 1342

      Gegeven: 648

    •    Aantal posts: 8.569

    Eruit op 2,83...2 dollar centjes winst p/a lol.
    Kijk wel wat het aandeel volgende week gaat doen.

    vrgr
  16. [verwijderd] 18 april 2016 13:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bio Blast Pharma Ltd (NASDAQ:ORPN) Receives Average Rating of “Strong Buy” from Brokerages

    Posted by Tony Sherman on Apr 18th, 2016 // No Comments


    Bio Blast Pharma logoShares of Bio Blast Pharma Ltd (NASDAQ:ORPN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

    Analysts have set a 12-month consensus price objective of $23.00 for the company and are expecting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given Bio Blast Pharma an industry rank of 95 out of 265 based on the ratings given to its competitors.
70 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.482
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.206
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.528
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.651
Aedifica 3 901
Aegon 3.258 322.664
AFC Ajax 538 7.086
Affimed NV 2 6.288
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.294
Air France - KLM 1.025 34.999
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.333
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.752
AMG 971 133.100
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.936
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.582
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.082
ASML 1.766 106.069
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390